A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway

Trial Profile

A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Interstitial cystitis
  • Focus Therapeutic Use
  • Acronyms LEADERSHIP
  • Sponsors Aquinox Pharmaceuticals
  • Most Recent Events

    • 04 Aug 2016 Results were presented at the Annual Meeting of the Canadian Urological Association (CUA) 2016, according to an Aquinox Pharmaceuticals media release.
    • 10 May 2016 Results assessing plasma and urinary pharmacokinetics (n=35) presented at the 111th Annual Meeting of the American Urological Association
    • 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top